{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:44:42Z","timestamp":1777502682056,"version":"3.51.4"},"reference-count":16,"publisher":"Baishideng Publishing Group Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJH"],"published-print":{"date-parts":[[2010]]},"DOI":"10.4254\/wjh.v2.i4.162","type":"journal-article","created":{"date-parts":[[2010,4,28]],"date-time":"2010-04-28T00:42:30Z","timestamp":1272415350000},"page":"162","source":"Crossref","is-referenced-by-count":8,"title":["Guillain-Barre syndrome associated with peginterferon alfa-2a for chronic hepatitis C: A case report"],"prefix":"10.4254","volume":"2","author":[{"given":"Mumtaz A","family":"Niazi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"ref1","unstructured":"World Health Organization. Hepatitis C. Last updated: 2008-01-25. Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/immunization\/topics\/hepatitis_c\/en\/index.html\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.who.int\/immunization\/topics\/hepatitis_c\/en\/index.html<\/ext-link>."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Kim WR. The burden of hepatitis C in the United States. Hepatology 2002;36:S30-S34.","DOI":"10.1002\/hep.1840360705"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 2007;14:107-115.","DOI":"10.1111\/j.1365-2893.2006.00785.x"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, Management, and Treatment of Hepatitis C: An Update. Hepatology 2009;49:1335-1374.","DOI":"10.1002\/hep.22759"},{"key":"ref5","unstructured":"PEGASYS&reg; Pegylated interferon (peginterferon) alfa-2a: Drug information. Hoffmann-La Roche Inc;2009. ."},{"key":"ref6","unstructured":"Lee MY, Cho H, Kim YM, Lee JS. [A case of Bell&rsquo;s palsy associated with peginterferon Alfa-2a and ribavirin therapy for chronic hepatitis C virus infection]. Korean J Hepatol 2006;12:444-448."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Khiani V, Kelly T, Shibli A, Jensen D, Mohanty SR. Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon alpha 2a therapy for chronic hepatitis C virus infection. World J Gastroenterol 2008;14:318-321.","DOI":"10.3748\/wjg.14.318"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Hirotani M, Nakano H, Ura S, Yoshida K, Niino M, Yabe I, Sasaki H. Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha. Intern Med 2009;48:373-375.","DOI":"10.2169\/internalmedicine.48.1616"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Meriggioli MN, Rowin J. Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha. Muscle Nerve 2000;23:433-435.","DOI":"10.1002\/(SICI)1097-4598(200003)23:3<433::AID-MUS17>3.0.CO;2-O"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Criteria for diagnosis of Guillain-Barr&eacute; syndrome. Ann Neurol 1978;3:565-566.","DOI":"10.1002\/ana.410030628"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N. Axonal Guillain-Barr&eacute; syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 2000;48:624-631.","DOI":"10.1002\/1531-8249(200010)48:4<624::AID-ANA9>3.0.CO;2-O"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Ropper AH. The Guillain-Barr&eacute; syndrome. N Engl J Med 1992;326:1130-1136.","DOI":"10.1056\/NEJM199204233261706"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Spudich SS, Nilsson AC, Lollo ND, Liegler TJ, Petropoulos CJ, Deeks SG, Paxinos EE, Price RW. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis 2005;5:98.","DOI":"10.1186\/1471-2334-5-98"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Haber P, DeStefano F, Angulo FJ, Iskander J, Shadomy SV, Weintraub E, Chen RT. Guillain-Barr&eacute; syndrome following influenza vaccination. JAMA 2004;292:2478-2481.","DOI":"10.1001\/jama.292.20.2478"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Gordon PH, Wilbourn AJ. Early electrodiagnostic findings in Guillain-Barr&eacute; syndrome. Arch Neurol 2001;58:913-917.","DOI":"10.1001\/archneur.58.6.913"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Miller RG, Sladky JT, Stevens JC. Practice parameter: immunotherapy for Guillain-Barr&eacute; syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003;61:736-740.","DOI":"10.1212\/WNL.61.6.736"}],"container-title":["World Journal of Hepatology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:58:01Z","timestamp":1559059081000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1948-5182\/full\/v2\/i4\/162.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.4254\/wjh.v2.i4.162","relation":{},"ISSN":["1948-5182"],"issn-type":[{"value":"1948-5182","type":"print"}],"subject":[],"published":{"date-parts":[[2010]]}}}